CSL Ltd Annual Report 2021

CSL’s 2030 strategy was developed to maximise our capabilities and advantages in a competitive and changing world. Historically and to this day, we have the most efficient supply chain from collections through to finished product for plasma-derived protein therapeutics, a business that has grown sustainably in recent years and does not face patent cliffs. Our differentiated cell-based influenza products offer communities improved protection against seasonal influenza and our extensive experience in rare disease allows us to focus on patients in our core therapeutic areas, delivering next generation innovative products across multiple platforms. Plasma collections have been adversely impacted over the last year by the COVID-19 pandemic as communities respond to shelter-in-place orders, extended lockdowns, multiple stimulus initiatives and other government actions. In response to these challenging conditions, we have implemented multiple initiatives and we are starting to see a recovery in plasma collections. CSL’s core plasma products are effective in treating chronic disease and we are confident that COVID-19 has not impacted demand for these lifesaving products. We expect to return to our growth trajectory in the coming years. Demand for influenza vaccine products has never been higher. We delivered a record number of doses worldwide last year amid heightened vigilance due to COVID. We expect this to continue in the coming years as the awareness of the burden of infectious disease grows. We are committed to the public health of Australia, having worked with partners in industry and government to supply 50 million doses of AstraZeneca COVID-19 vaccine to communities across the nation. We believe the 2030 strategy is resilient in the face of the challenges today and will make us stronger. Our efforts over the last year have focused on maintaining our leadership position and preparing for strong growth when market forces become favourable. Our 2030 strategy C S L P e o p l e & C u l t u r e Patients and Public Health • Immunology • Haematology • Transplant • Respiratory • Cardiovascular and Metabolic • Influenza E f fi c i e n c y & F o c u s I n n o v a t i o n S u s t a i n a b l e G r o w t h D i g i t a l T r a n s f o r m a t i o n R e l i a b l e S u p p l y • Products • Delivery • Services • Technology • Technology • Process Improvement • Operational Excellence • Capital Project Execution Growth Platforms • Plasma • Recombinants • Cell & Gene Therapy • Influenza Vaccines • Business Model • Connected Healthcare • New Capabilities We are continually investigating new ways to bring lifesaving therapies to patients across the globe. We are also expanding production tomeet future expected demand. The current decade will bring advancements inmedicine and technology as part of a continued evolution of biotechnology. It is an evolution that we are excited to be a part of and our 2030 strategy is developed with this evolution at its heart. CSL Limited Annual Report 2020/21 14 4 Our Strategy and Performance